Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 27761-27770 Newer>

The Motley Fool December 20, 2007 Anders Bylund	Read Oracle's Tea Leaves: Fool by Numbers The fast facts on software provider Oracle's second-quarter earnings, in which sales of business applications grew all over the globe.
The Motley Fool December 20, 2007 Alyce Lomax	Invest in the Future There are many ways to invest in a sustainable future; socially responsible investing can show impressive returns.
The Motley Fool December 20, 2007 Anders Bylund	Foolish Forecast: Pop the Research In Motion Bubble In advance of earnings, analysts compare Research In Motion to some of its peers and competitors.
The Motley Fool December 20, 2007 Selena Maranjian	How I Tripled My Money in a Year The more your money multiplies, the easier its growth gets.
The Motley Fool December 19, 2007 Anders Bylund	Foolish Forecast: Micron's Puny Prospects In advance of earnings, let's take a look at memory specialist Micron Technology to see how the company compares to some of its peers.
The Motley Fool December 19, 2007 Dave Mock	Jobs Caught Fishing in Japan Word has spread that Apple has been in separate talks with NTT DoCoMo and Softbank about offering the iPhone in tech-savvy Japan.
The Motley Fool December 19, 2007 Rich Smith	Lockheed's Plane for All Seasons Lockheed unveils the second version of its Lockheed F-35 Lightning II for the U.S. Marine Corps, but the first deliveries to the military are still at least three years away.
The Motley Fool December 19, 2007 Toby Shute	2008: An Oil Patch Preview It was a great year for energy investments, but what can we expect in the year ahead?
The Motley Fool December 19, 2007 Anders Bylund	Palm Rewrites the Dictionary In Palm's just-reported second quarter there was 11% lower revenue compared to the year-ago period, along with negative operating cash flow and net income.
The Motley Fool December 19, 2007 Brian Lawler	Novartis' Diabetes Battle Can Begin Novartis gets set to market a novel diabetes treatment, with EU approval that is not all it had hoped for.
<Older 27761-27770 Newer> Return to current articles.